Daichao Wu

Prof. Daichao Wu

Department of Histology and Embryology, Hengyang Medical College, University of South China, Hengyang, Hunan, 421001, China.
+1
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
DWDaichao Wu
Daichao Wu
DGD. Travis Gallagher
D. Travis Gallagher
RGRagul Gowthaman
Ragul Gowthaman
BPBrian G. Pierce
Brian G. Pierce
RMRoy A. Mariuzza
Roy A. Mariuzza
Adoptive cell therapy (ACT) with tumor-specific T cells can mediate cancer regression. The main target of tumor-specific T cells are neoantigens arising from mutations in self-proteins. Although the majority of cancer neoantigens are unique to each patient, and therefore not broadly useful for ACT, some are shared. We studied oligoclonal T-cell receptors (TCRs) that recognize a shared neoepitope arising from a driver mutation in the p53 oncogene (p53R175H) presented by HLA-A2. Here we report structures of wild-type and mutant p53–HLA-A2 ligands, as well as structures of three tumor-specific TCRs bound to p53R175H–HLA-A2. These structures reveal how a driver mutation in p53 rendered a self-peptide visible to T cells. The TCRs employ structurally distinct strategies that are highly focused on the mutation to discriminate between mutant and wild-type p53. The TCR–p53R175H–HLA-A2 complexes provide a framework for designing TCRs to improve potency for ACT without sacrificing specificity.

1 January 2018 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
DWDaichao Wu
Daichao Wu
MGMing Guo
Ming Guo
XMXiaoli Min
Xiaoli Min
SDShuyan Dai
Shuyan Dai
MLMeixiang Li
Meixiang Li
Yongheng ChenYongheng Chen
Yongheng Chen
LY2874455 can avoid a steric clash with the mutated gatekeeper residue in FGFR4.